<DOC>
	<DOCNO>NCT00006734</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . It yet know chemotherapy regimen combine radiation therapy and/or surgery effective treat Ewing 's sarcoma primitive neuroectodermal tumor . PURPOSE : Randomized phase III trial compare effectiveness different chemotherapy regimen combine radiation therapy and/or surgery treat patient Ewing 's sarcoma primitive neuroectodermal tumor .</brief_summary>
	<brief_title>Comparison Combination Chemotherapy Regimens Treating Patients With Ewing 's Sarcoma Neuroectodermal Tumor</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect interval-compressed vs standard chemotherapy term event-free survival overall survival patient newly diagnose , localize Ewing 's sarcoma peripheral primitive neuroectodermal tumor . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( 18 year vs 18 year ) location primary disease ( pelvic v nonpelvic ) . Patients randomize 1 2 treatment arm induction continuation therapy . - Induction therapy ( week 1-12 ) : - Arm I : Patients receive alternate course chemotherapy consist vincristine IV day 1 , doxorubicin IV continuously 48 hour day 1 2 , cyclophosphamide IV 1 hour day 1 course 1 3 ifosfamide IV 1 hour etoposide IV 1-2 hour day 1-5 course 2 4 . Beginning 24 hour last dose chemotherapy course , patient receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily blood count recover . Treatment continue every 3 week 4 course . - Arm II : Patients receive alternate course chemotherapy consist vincristine , doxorubicin , cyclophosphamide arm I course 1 , 3 , 5 ifosfamide etoposide arm I course 2 , 4 , 6 . Patients also receive G-CSF arm I . Treatment continue every 2 week 6 course . After completion induction therapy , patient arm receive local control treatment primary tumor . Patients receive continuation chemotherapy surgery concurrently radiotherapy . - Continuation therapy : - Arm I ( week 13-42 ) : Patients receive additional alternating course chemotherapy arm I induction therapy exception vincristine cyclophosphamide alone course 7 and/or 11 and/or 13 . Patients also receive G-CSF induction therapy . Treatment continue every 3 week 10 course . - Arm II ( week 13-29 ) : Patients receive additional alternating course chemotherapy arm II induction therapy exception vincristine cyclophosphamide alone course 9 and/or 11 and/or 13 . Patients also receive G-CSF induction therapy . Treatment continue every 2 week 8 course . Patients follow every 3 month 4 year every 6 month 1 year . PROJECTED ACCRUAL : Approximately 528 patient accrue study within 4-5 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm localized Ewing 's sarcoma peripheral primitive neuroectodermal tumor ( PNET ) bone soft tissue Diagnostic biopsy primary tumor within 30 day study Paraspinal bony skull tumor extradural origin allow No intradural soft tissue tumor Askin 's tumor chest wall allow Chest wall tumor ipsilateral pleural effusion ipsilateral pleuralbased secondary tumor nodule allow No contralateral pleural effusion No metastatic disease distant node involvement One pulmonary pleural nodule great 1 cm diameter OR 1 nodule great 0.5 cm diameter consider pulmonary metastasis Solitary lung nodule 0.51 cm OR multiple nodule 0.30.5 cm allow unless biopsy positive tumor Light microscopic appearance ( hematoxylin eosin stain ) consistent Ewing 's sarcoma peripheral PNET No immunohistochemical ultrastructural evidence rhabdomyosarcoma No esthesioneuroblastoma Clinically pathologically involve regional lymph node allow No CNS involvement PATIENT CHARACTERISTICS : Age : 50 diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine normal age Creatinine clearance isotope glomerular filtration rate least 75 mL/min Cardiovascular : Shortening fraction least 28 % echocardiography OR Ejection fraction least 55 % radionuclide angiogram Other : Not pregnant nursing Fertile patient must use effective contraception No prior malignancy except skin cancer diagnose least 5 year ago currently remission PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy skin cancer No concurrent sargramostim ( GMCSF ) No concurrent pegfilgrastim Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Prior complete partial excision primary tumor allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>localize Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>